232 related articles for article (PubMed ID: 34623544)
1. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
Sabbah HN
Heart Fail Rev; 2022 Sep; 27(5):1911-1923. PubMed ID: 34623544
[TBL] [Abstract][Full Text] [Related]
2. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
3. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.
Sabbah HN; Taylor C; Vernon HJ
Future Cardiol; 2023 Mar; 19(4):211-225. PubMed ID: 37325898
[TBL] [Abstract][Full Text] [Related]
4. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
Reid Thompson W; Hornby B; Manuel R; Bradley E; Laux J; Carr J; Vernon HJ
Genet Med; 2021 Mar; 23(3):471-478. PubMed ID: 33077895
[TBL] [Abstract][Full Text] [Related]
5. Mechano-energetic aspects of Barth syndrome.
Dudek J; Maack C
J Inherit Metab Dis; 2022 Jan; 45(1):82-98. PubMed ID: 34423473
[TBL] [Abstract][Full Text] [Related]
6. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
7. Current and future treatment approaches for Barth syndrome.
Thompson R; Jefferies J; Wang S; Pu WT; Takemoto C; Hornby B; Heyman A; Chin MT; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):17-28. PubMed ID: 34713454
[TBL] [Abstract][Full Text] [Related]
8. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
9. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
Van den Eynde J; Chinni B; Vernon H; Thompson WR; Hornby B; Kutty S; Manlhiot C
Orphanet J Rare Dis; 2023 Apr; 18(1):76. PubMed ID: 37041653
[TBL] [Abstract][Full Text] [Related]
10. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
11. Cardiolipin metabolism and its causal role in the etiology of the inherited cardiomyopathy Barth syndrome.
Gaspard GJ; McMaster CR
Chem Phys Lipids; 2015 Dec; 193():1-10. PubMed ID: 26415690
[TBL] [Abstract][Full Text] [Related]
12. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
13. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
Zegallai HM; Hatch GM
Mol Cell Biochem; 2021 Mar; 476(3):1605-1629. PubMed ID: 33415565
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome.
Gebert N; Joshi AS; Kutik S; Becker T; McKenzie M; Guan XL; Mooga VP; Stroud DA; Kulkarni G; Wenk MR; Rehling P; Meisinger C; Ryan MT; Wiedemann N; Greenberg ML; Pfanner N
Curr Biol; 2009 Dec; 19(24):2133-9. PubMed ID: 19962311
[TBL] [Abstract][Full Text] [Related]
15. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
Huang Y; Powers C; Moore V; Schafer C; Ren M; Phoon CK; James JF; Glukhov AV; Javadov S; Vaz FM; Jefferies JL; Strauss AW; Khuchua Z
Orphanet J Rare Dis; 2017 Mar; 12(1):49. PubMed ID: 28279226
[TBL] [Abstract][Full Text] [Related]
16. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
17. Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes.
Aryal B; Rao VA
PLoS One; 2016; 11(7):e0158376. PubMed ID: 27434059
[TBL] [Abstract][Full Text] [Related]
18. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Hornby B; Thompson WR; Almuqbil M; Manuel R; Abbruscato A; Carr J; Vernon HJ
Orphanet J Rare Dis; 2022 Sep; 17(1):336. PubMed ID: 36056411
[TBL] [Abstract][Full Text] [Related]
19. Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.
Koenig MK; Russo SN; McBride KL; Bjornsson HT; Gunnarsdottir BB; Goldstein A; Falk SA
JIMD Rep; 2023 Jan; 64(1):65-70. PubMed ID: 36636586
[TBL] [Abstract][Full Text] [Related]
20. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
